Baxter Healthcare Corporation recalled 13,000 containers of Acetaminophen Injection on August 20, 2025. The recall follows reports of discoloration that may affect product safety. Consumers should stop using the medication immediately and contact their healthcare providers for guidance.
Discoloration
Consumers and healthcare providers should stop using this product immediately. Contact Baxter Healthcare Corporation or your healthcare provider for guidance. Notification method: Letter
The recall involves Acetaminophen Injection 1000 mg/100 mL packaged in 100 mL Viaflo containers. The product is available by prescription only and has a lot number of 24A27G66 with an expiration date of December 31, 2025.
The discoloration of the Acetaminophen Injection poses potential safety risks. This defect falls under Class II recall, indicating a moderate risk of adverse health consequences.
As of now, there are no reported injuries or incidents related to the discoloration of this product. Consumers are urged to remain vigilant and report any adverse effects to their healthcare provider.
Stop using the Acetaminophen Injection immediately. Contact Baxter Healthcare Corporation or your healthcare provider for further instructions. Notifications have been sent via letter.
For more information, consumers can reach Baxter Healthcare Corporation at 1-800-XXX-XXXX. Additional details are available at the FDA's recall page.
Get notified about recalls in categories you care about.
Bristol-Myers Squibb recalled 12,778 vials of Opdualag injection on October 21, 2025. The recall stems from a lack of assurance of sterility. The affected products were distributed nationwide in the United States.
Major Pharmaceuticals recalled Gabapentin Capsules, USP, 100 mg, on October 10, 2025, due to failed impurities specifications. The recall affects several lot numbers distributed nationwide. Consumers must stop using the affected capsules immediately.
Lannett Company, Inc. recalled 46,848 bottles of Niacin Extended-release Tablets on October 10, 2025. The recall follows reports of failed dissolution specifications, which could affect medication effectiveness. Consumers should stop using the product immediately and consult healthcare providers for guidance.